Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Actelion Tracleer Promotion Cited By FDA For False Statements On CHF

  • News

Executive Summary

FDA is directing Actelion to stop promoting Tracleer for unapproved use in the treatment of congestive heart failure

You may also be interested in...



Actelion Tracleer Label Revision: No Efficacy For Congestive Heart Failure

Actelion's Tracleer (bosentan) is "not effective" in treating congestive heart failure, new labeling for the endothelin receptor antagonist states

Actelion Tracleer Label Revision: No Efficacy For Congestive Heart Failure

Actelion's Tracleer (bosentan) is "not effective" in treating congestive heart failure, new labeling for the endothelin receptor antagonist states

Actelion Will Launch Tracleer Through Closed Distribution System

Actelion's launch of the pulmonary hypertension drug Tracleer will include converting 200 patients in an ongoing, open-label trial to its closed commercial distribution system, the company told analysts Nov. 21

Table

View full table

Tags:
UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By